生長激素缺乏症市場規模、佔有率和成長分析：按品牌、按應用、按最終用戶、按地區 - 行業預測，2024-2031 年

生長激素缺乏症市場規模將於2022 年達到34.7 億美元，從2023 年的37 億美元成長到2031 年的61.2 億美元，在預測期內（2024-2031 年）預計將以6.50% 的複合年成長率成長。

由腦損傷、遺傳性疾病、先天性疾病和特殊治療等因素引起的生長激素缺乏症 (GHD) 的盛行率不斷增加，導致對生長激素治療的需求增加。根據美國國家生物技術資訊中心 (NCBI) 的數據，在英國，大約每 3,500 至 4,000 名兒童中就有 1 人患有兒童生長激素缺乏症。這種不斷上升的發病率正在透過不斷增加的研發來推動產業成長。 2022年2月，輝瑞和OPKO獲得了歐盟（EU）每週一次的NGENLA（TM）（somatrogon）注射的上市核准，這是該領域的一個重要里程碑。

目錄

介紹

• 這項研究的目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 次要/一級資訊來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 技術分析
• 價值鏈分析
• 價格分析
• Start-Ups分析
• 監管環境
• 專利分析
• 管道分析
• 關鍵成功因素
• 市場吸引力指數
• 競爭程度
• 關鍵投資機會
• 生態系繪圖

生長激素缺乏症市場：依品牌

• 市場概況
• 去甲腎上腺素
• Genotropin
• Humatrope
• 齊前
• 全向

生長激素缺乏症市場：依應用分類

• 市場概況
• 生長激素缺乏症
• 透納氏症
• 原發性矮小症
• 普瑞德威利症候群
• 與胎齡相比較小
• 其他

生長激素缺乏症市場：依最終用戶分類

• 市場概況
• 醫院藥房
• 零售藥房
• 網路藥房
• 專業藥房

生長激素缺乏症市場規模：按地區

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Pfizer（US）
• Eli Lilly and Company（US）
• Genentech（US）
• Novo Nordisk（Denmark）
• Merck & Co.（US）
• Sandoz International（Switzerland）
• Ferring Pharmaceuticals（Switzerland）
• Ipsen（France）
• Teva Pharmaceutical Industries（Israel）
• GeneScience Pharmaceuticals（China）
• LG Chem（South Korea）
• Anhui Anke Biotechnology Group（China）
• Biopartners（Switzerland）
• Procter & Gamble（US）
• Endo International（Ireland）
• LG Life Sciences（South Korea）
• Versartis（US）
• Opko Health（US）
• LG Electronics（South Korea）
• Rani Therapeutics（US）

Growth Hormone Deficiency Market size was valued at USD 3.47 billion in 2022 and is poised to grow from USD 3.70 billion in 2023 to USD 6.12 billion by 2031, growing at a CAGR of 6.50% in the forecast period (2024-2031).

The increasing prevalence of growth hormone deficiency (GHD), caused by factors such as brain injuries, genetic disorders, congenital conditions, and specific medical treatments, has led to a rising demand for growth hormone therapies. According to the National Center for Biotechnology Information (NCBI), pediatric growth hormone deficiency affects approximately 1 in every 3,500-4,000 children in the United Kingdom. This rising incidence has driven industry growth, supported by intensified research and development efforts. A significant milestone occurred in February 2022 when Pfizer and OPKO received marketing authorization from the European Union for their Once-Weekly NGENLA(TM) (somatrogon) Injection, marking a notable advancement in the field.

Top-down and bottom-up approaches were used to estimate and validate the size of the Growth Hormone Deficiency market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Growth Hormone Deficiency Market Segmental Analysis

Growth Hormone Deficiency Market is segmented on the basis of brand, application and end user. Based on brand, the market is segmented into Norditropin, Genotropin, Humatrope, Saizen, and Omnitrope. Based on application, the market is segmented into Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Others. Based on End User, it is bifurcated into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy. Based on region, it is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Drivers of the Growth Hormone Deficiency Market

Human growth hormone (HGH), also known as somatotropin, is crucial in human development as it promotes cell growth, division, and regeneration. Inadequate production of growth hormone (GH) by the pituitary gland results in hGH deficiency in humans. Treatment typically involves administering recombinant human growth hormone via subcutaneous injection. Genetic conditions like Prader-Willi syndrome and Turner syndrome, which are marked by delayed puberty and shorter stature, can also lead to insufficient growth hormone levels.

Restraints in the Growth Hormone Deficiency Market

The expenses linked with human growth hormone (HGH) therapy pose a significant obstacle, restricting access for many patients and posing challenges to healthcare systems. A 2022 study published in a medical journal underscored the substantial financial burden experienced by both patients and healthcare systems. This has drawn attention to the necessity for flexibility and potential adjustments in pricing. Achieving broad access to HGH treatment necessitates tackling the financial hurdles associated with its high cost.

Market Trends of the Growth Hormone Deficiency Market

The pharmaceutical sector is set for substantial expansion thanks to rapid advancements in drug delivery methods. Innovations like wearables, needle-free devices, and autoinjectors have played a pivotal role in enhancing comfort levels and patient adherence to growth hormone therapy. Particularly noteworthy are the swift development of long-acting drugs and implantable devices, which enable extended delivery periods and less frequent dosing of growth hormone. These advancements not only enhance clinical outcomes but also elevate the overall patient experience, thereby broadening the accessibility and effectiveness of growth hormone therapies.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Pricing Analysis
• Start Up Analysis
• Regulatory Landscape
• Patent Analysis
• Pipeline Analysis
• Key Success Factors
• Market Attractiveness Index
• Degree of Competition
• Top Investment Pockets
• Ecosystem Mapping

Growth Hormone Deficiency Market by Brand

• Market Overview
• Norditropin
• Genotropin
• Humatrope
• Saizen
• Omnitrope

Growth Hormone Deficiency Market by Application

• Market Overview
• Growth Hormone Deficiency
• Turner Syndrome
• Idiopathic Short Stature
• Prader-Willi Syndrome
• Small For Gestational Age
• Others

Growth Hormone Deficiency Market by End User

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Specialty Pharmacy

Growth Hormone Deficiency Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Pfizer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneScience Pharmaceuticals (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LG Chem (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anhui Anke Biotechnology Group (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biopartners (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Procter & Gamble (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo International (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LG Life Sciences (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Versartis (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Opko Health (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LG Electronics (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rani Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments